Acute lymphoblastic leukemia other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
(Category)
Line 13: Line 13:
A [[biopsy]] is the only sure way to know whether leukemia cells are in the bone marrow. Before the sample is taken, local anesthesia is used to numb the area. This helps reduce the pain. Bone marrow from your hipbone or another large bone is taken as biopsy.<ref>[http://www.accessmedicine.com/content.aspx?aID=65842 Harrison's Principles of Internal Medicine, 16th EditioN,] Chapter 97. Malignancies of Lymphoid Cells. Clinical Features, Treatment, and Prognosis of Specific Lymphoid Malignancies.</ref>
A [[biopsy]] is the only sure way to know whether leukemia cells are in the bone marrow. Before the sample is taken, local anesthesia is used to numb the area. This helps reduce the pain. Bone marrow from your hipbone or another large bone is taken as biopsy.<ref>[http://www.accessmedicine.com/content.aspx?aID=65842 Harrison's Principles of Internal Medicine, 16th EditioN,] Chapter 97. Malignancies of Lymphoid Cells. Clinical Features, Treatment, and Prognosis of Specific Lymphoid Malignancies.</ref>


A bone marrow biopsy and aspirate are routinely performed even in T-cell acute lymphoblastic leukemia to determine the extent of marrow involvement. Malignant cells should be sent for conventional cytogenetic studies, as detection of the Ph1 t(9;22), myc gene rearrangements (in Burkitt leukemia), and Myeloid lymphocytic leukemia gene rearrangements add important prognostic information<ref name=ALL>{{cite web | title = National Cancer Institute| url =http://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq#link/_44_toc }}</ref>
A bone marrow biopsy and aspirate are routinely performed even in T-cell acute lymphoblastic leukemia to determine the extent of marrow involvement. Malignant cells should be sent for conventional cytogenetic studies, as detection of the Ph1 t(9;22), myc gene rearrangements (in Burkitt leukemia), and ''MLL'' gene rearrangements add important prognostic information<ref name=ALL>{{cite web | title = National Cancer Institute| url =http://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq#link/_44_toc }}</ref>


==Flow cytometry==
==Flow cytometry==

Revision as of 01:53, 27 December 2018

Acute lymphoblastic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Acute lymphoblastic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Bone X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute lymphoblastic leukemia other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute lymphoblastic leukemia other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute lymphoblastic leukemia other diagnostic studies

CDC on Acute lymphoblastic leukemia other diagnostic studies

Acute lymphoblastic leukemia other diagnostic studies in the news

Blogs on Acute lymphoblastic leukemia other diagnostic studies

Directions to Hospitals Treating Acute lymphoblastic leukemia

Risk calculators and risk factors for Acute lymphoblastic leukemia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Carlos A Lopez, M.D. [3]

Overview

Other diagnostic studies for acute lymphoblastic leukemia include cytogenetics, bone marrow biopsy, flow cytometry, RT-PCR and FISH.

Cytogenetics

Cytogenetics (particularly the presence of Philadelphia chromosome) and immunophenotyping, establish whether the "blast" cells began from the B lymphocytes or T lymphocytes. DNA testing can establish how aggressive the disease is; different mutations have been associated with shorter or longer survival.

Biopsy

A biopsy is the only sure way to know whether leukemia cells are in the bone marrow. Before the sample is taken, local anesthesia is used to numb the area. This helps reduce the pain. Bone marrow from your hipbone or another large bone is taken as biopsy.[1]

A bone marrow biopsy and aspirate are routinely performed even in T-cell acute lymphoblastic leukemia to determine the extent of marrow involvement. Malignant cells should be sent for conventional cytogenetic studies, as detection of the Ph1 t(9;22), myc gene rearrangements (in Burkitt leukemia), and MLL gene rearrangements add important prognostic information[2]

Flow cytometry

Flow cytometry should be performed to characterize expression of lineage-defining antigens and allow determination of the specific acute lymphoblastic leukemia subtype.[2]

RT-PCR and FISH

  • In addition, for B-cell disease the malignant cells should be analyzed using RT-PCR and FISH for evidence of the bcr-abl fusion gene. This last point is of utmost importance, as timely diagnosis of Ph1 acute lymphoblastic leukemia will significantly change the therapeutic approach.[2]

References

  1. Harrison's Principles of Internal Medicine, 16th EditioN, Chapter 97. Malignancies of Lymphoid Cells. Clinical Features, Treatment, and Prognosis of Specific Lymphoid Malignancies.
  2. 2.0 2.1 2.2 "National Cancer Institute".

Template:WH Template:WS